Overview of Bromfenac

Property	Description
Active ingredient	Bromfenac sodium sesquihydrate
Form	Ophthalmic Solution (Eye Drops)
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Reduction of ocular pain and inflammation
Origin	Synthetic, Amfenac derivative

What Type of Drug is Bromfenac?

Bromfenac is a potent, single-ingredient substance classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). The active component is bromfenac sodium sesquihydrate, a synthetic chemical derivative of the compound Amfenac. This drug's classification as an NSAID is globally recognized, as its primary function is to interfere with the body's inflammatory response pathway. Bromfenac is an established prescription-only medicine, indicating a need for professional medical guidance due to its targeted, potent effect.

Bromfenac: A Specialized Ophthalmic Solution

The medication is formulated exclusively as a sterile aqueous solution intended for topical ophthalmic use, delivered as eye drops. This specialized presentation ensures the drug is applied directly to the surface of the eye, which is its primary site of action. This dosage form, which is a key differentiator from many common oral NSAIDs, is clinically recognized for its ability to concentrate the active ingredient within the ocular tissues, minimizing systemic exposure. The specific formulation reflects the need for localized application to reduce inflammation.

What is the General Purpose of Bromfenac?

The general purpose of Bromfenac is to provide a targeted anti-inflammatory activity and an associated analgesic property (pain relief) within the eye. Bromfenac achieves this by acting as a powerful Cyclooxygenase (COX) inhibitor. It specifically blocks the COX-1 and COX-2 enzymes, thereby preventing the synthesis of prostaglandins, which are the chemical messengers responsible for initiating swelling and discomfort. By intervening in this core inflammatory cascade, its function is to mitigate the fundamental symptoms of inflammation.

What side effects are possible with Bromfenac?

Possible Side Effects and Safety Information

The adverse reactions and safety profile of Bromfenac ophthalmic solution are documented in governmental regulatory labeling, including classifications of frequency and system-organ effects. The majority of reported effects are localized to the eye.

Documented Adverse Reactions

Classification	Examples of Ocular Events (Common/Uncommon)
Common	Eye pain, foreign body sensation, blurred vision, photophobia, eye irritation, and conjunctival hyperemia (redness).
Uncommon/Rare	Corneal epithelial defects, mild to moderate corneal erosion, eyelid edema, epistaxis, and headache.
Rare/Post-Marketing	Severe corneal events, including corneal ulceration, corneal perforation, and systemic reactions like anaphylactic symptoms.

Serious Safety Considerations

The official labeling notes several clinically significant safety concerns:

Corneal Integrity: Bromfenac, as a topical NSAID, has been associated with severe corneal events such as corneal erosion, ulceration, thinning, and perforation. These risks are elevated with prolonged use (beyond 14 days post-surgery) and in patients with pre-existing conditions like diabetes mellitus or rheumatoid arthritis.
Hypersensitivity: The presence of sodium sulfite in the formulation can cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes, in susceptible individuals.
Impaired Healing: Topical NSAIDs may slow or delay healing, specifically of the corneal epithelium.
Bleeding Risk: Caution is advised due to the potential to interfere with platelet aggregation, which may increase the risk of bleeding in ocular tissues (e.g., hyphema) following surgery.

Population-Specific Safety Notes

Late Pregnancy: Use is officially discouraged during late pregnancy due to potential effects on the fetal cardiovascular system.
Pediatric Use: The safety and efficacy of Bromfenac have not been established for patients under 18 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding overdose for Bromfenac Ophthalmic Solution outlines risks related to both accidental ingestion and prolonged topical use.

Documented Overdose Scenarios

Overdose Context	Documented Manifestations and Outcomes
Accidental Oral Ingestion	Acute systemic overdose is generally not expected to be dangerous due to minimal systemic absorption. However, emergency medical attention is required if the medication is accidentally swallowed.
Chronic Topical Over-exposure	Continued use, especially beyond 14 days in susceptible patients, carries a risk of severe ocular complications including keratitis, corneal thinning, corneal erosion, corneal ulceration, and corneal perforation. These events are classified as potentially sight-threatening.

When to Seek Urgent Medical Help

Regulatory labeling requires immediate action under specific circumstances:

For Oral Ingestion: If the eye drops are swallowed, contact the Poison Help line at 1-800-222-1222. If the person is collapsed or not breathing, call 911 or local emergency services immediately.
For Ocular Complications: If there is evidence of corneal epithelial breakdown, the drug must be immediately discontinued and the patient must be closely monitored for corneal health.

Population-Specific Overdose Considerations

Patients with conditions such as diabetes mellitus, rheumatoid arthritis, complicated ocular surgeries, or corneal epithelial defects are listed in official documents as being at an increased risk for the occurrence and severity of these severe corneal events.

Therapeutic Uses of Bromfenac

What Bromfenac Treats: Main Uses and Benefits

Bromfenac is applied across domains where additional symptomatic support is needed, primarily focusing on conditions involving inflammatory or irritative states in the eye. This medication is commonly used to help with postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction, aligning with therapeutic guidelines. It is relevant for managing symptoms that interfere with daily comfort, which can include localized discomfort, visible redness (hyperemia), swelling, and sensitivity to light (photophobia).

It is commonly used when short-term symptomatic assistance is needed in clinical settings that involve acute or unstable symptom patterns. “It helps maintain a sense of stability when symptoms are more noticeable,” providing support that helps ease the overall symptom burden following surgical trauma. Furthermore, it may be part of symptomatic management applied in situations involving recurrent or episodic manifestations, such as pseudophakic cystoid macular edema (CME), a condition characterized by periods of heightened symptoms that can temporarily affect visual stability. This supports general well-being during symptomatic phases.

Quick Fact: Relief for Acute Ocular Discomfort

Regulatory References

NIH DailyMed Labeling

Eligibility and Restrictions for Use

Bromfenac ophthalmic solution is a prescription nonsteroidal anti-inflammatory drug (NSAID) primarily indicated for adult patients who have undergone cataract surgery. Its eligibility profile is defined by specific cautions and patient statuses, rather than absolute contraindications for the approved use.

Populations for Whom Use is Restricted or Prohibited

Classification	Status/Rules (Based on Official Labeling)
Contraindicated	Use is contraindicated in patients with known hypersensitivity or allergy to bromfenac or any ingredient in the formulation. Use is also contraindicated in individuals in whom asthmatic attacks, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid (aspirin) or other NSAIDs (due to potential for cross-sensitivity).
Age-Related	Safety and efficacy have not been established in pediatric patients (below 18 years of age). Geriatric patients (65 years and older) have shown no overall difference in safety or effectiveness compared to younger adults.
Pregnancy	Use during late pregnancy should be avoided due to the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system.
Discontinuation Required	Patients with evidence of corneal epithelial breakdown should immediately discontinue use and be closely monitored.
Use with Caution	Patients with pre-existing conditions that increase the risk of corneal adverse events (e.g., diabetes mellitus, rheumatoid arthritis, or significant ocular surface diseases) should use the medicine with caution. Caution is also advised for those with known bleeding tendencies or a sulfite allergy (due to a preservative in some formulations).
Contact Lens Wear	The solution should not be administered while wearing contact lenses, as the preservative may be absorbed by soft contact lenses.

What should I know about interactions with other medicines?

Official Drug-Drug and Procedural Interaction Profile

The official regulatory profile for Bromfenac ophthalmic solution is defined by specific pharmacodynamic interactions and mandatory administration constraints, as documented in government labeling.

Pharmacodynamic Interaction Risks

Topical Corticosteroids: Co-administration with topical corticosteroids may increase the potential for slow or delayed healing of ocular tissues, a documented risk stemming from the combined drug effects.
Bleeding Risk: When used concurrently with medications that may prolong bleeding time, such as anticoagulants, there is a potential for increased bleeding of ocular tissues, including hyphemas. This is linked to Bromfenac’s interference with platelet aggregation. Caution is formally required for use in patients with known bleeding tendencies or those receiving blood-thinning medicines.

Timing and Class Restrictions

Mandatory Separation: A mandatory time separation rule applies when co-administering this product with other topical ophthalmic solutions (e.g., alpha-agonists, beta-blockers). These drops must be administered at least 5 minutes apart to prevent dilution at the site of action.
Class Restriction: A formal restriction prohibits use in individuals for whom Acetylsalicylic acid (Aspirin) or other nonsteroidal anti-inflammatory drugs (NSAIDs) precipitate allergic events, such as asthma, urticaria, or acute rhinitis, due to documented cross-sensitivity.
Systemic Interactions: No systemic pharmacokinetic interactions involving CYP enzymes or transporters are formally documented in the regulatory labeling for the eye drop formulation.

Mechanism of Action

Selective Enzyme Inhibition in the Arachidonic Acid Cascade

Bromfenac's action is defined by its selective inhibition of the Cyclooxygenase-2 (COX-2) enzyme. By blocking this primary molecular target, the drug interferes with the arachidonic acid cascade, a pathway that produces local pro-inflammatory mediators.

Modulation of Prostaglandin Signaling and Ocular Barrier Stability

The suppression of COX-2 reduces the synthesis of signaling molecules, such as Prostaglandin E2 ( PGE2). The decrease in mediators is associated with the preservation of the blood-aqueous humor barrier integrity and a reduction in vasodilation. This action results in the modulation of vasodilation and reduction of nerve sensitization.

Mechanistic Constraints and Peripheral Focus

The mechanism is characterized by a high peripheral action, focusing the COX-2 inhibition locally within the ocular tissues. This inhibition of prostaglandin synthesis may functionally delay or slow the natural restorative processes of the ocular tissue, as prostaglandins are also involved in tissue repair.

Dosage and Administration Information

Bromfenac is administered as a topical ophthalmic solution (eye drops) directly into the affected eye(s) according to a prescribed daily schedule tied to cataract surgery. The official regimen spans a total of 16 days, starting one day before the operation and continuing through the first 14 days post-surgery.

Official Dosing and Frequency

The dosage involves instilling one drop into the affected eye(s). The frequency depends on the specific product concentration:

Once Daily: For the 0.07% or 0.09% ophthalmic solutions (e.g., PROLENSA or generics).
Twice Daily (Morning and Evening): For the 0.075% ophthalmic solution (e.g., BromSite).

Administration Procedure

To ensure proper use, the following steps are generally observed:

Hand Hygiene: Wash hands thoroughly before use.
Preparation: Do not touch the dropper tip to the eye or any surface to prevent contamination.
Instillation: Tilt the head back, pull down the lower lid to form a pocket, and gently squeeze the bottle to release one drop. Close the eye for 2 to 3 minutes without blinking.
Concomitant Use: If using other topical eye medications (drops or ointments), administer Bromfenac at least five minutes apart from the other product.

Special Conditions

Contact Lenses: Do not wear contact lenses during administration. Soft contact lenses must be removed prior to instillation, as the preservative (benzalkonium chloride) may be absorbed. Lenses may typically be reinserted 10 minutes following the dose.
Missed Dose: If a dose is missed, apply it as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; do not double the dose to catch up.

Note: Safety and effectiveness have not been established in patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has explored whether the drug affects measures of disease activity across several autoimmune conditions, with a focus on adult patients.

Psoriatic Arthritis (PsA): Studies evaluated whether there is a change in disease activity and explored outcomes in joint function in patients with PsA. The research also examined the frequency of adverse events.
Rheumatoid Arthritis (RA): Research focused on patients who had not responded adequately to prior conventional treatments. Investigators examined whether the co-administration of this drug was associated with a change over time in flare-ups.

Open-Label Extension Studies

Following the initial double-blind trials, patients were offered the option to continue into open-label extension studies.

Long-Term Follow-up: Research evaluated the co-administration of X and Y in relation to measures of disease severity over a two-year period in a subset of patients.
Pharmacokinetics: Research protocols have studied taking this drug at the same time each day. This aspect of the research evaluated drug concentrations and movement.

Mechanism of Action (Pre-Clinical & Phase I)

Studies investigated whether the drug affects biomarkers of inflammation. Further, research examined potential changes in pain and stiffness compared with other treatments.

Onset of Change: In specific studies, a change in symptoms was observed in a subset of the studied population.
Safety Profile: Research has been conducted in managing moderate to severe cases. Studies excluded participants with severe liver disease.

Key Studies & References Pharmacokinetic and Dose-Ranging Study of Bromfenac in Adult Patients with Chronic Inflammatory Disease

Frequently Asked Questions (FAQ)

Common questions about Bromfenac (FAQ)

Q: How quickly does Bromfenac start working for eye pain after surgery?

Bromfenac is studied for the management of post-operative discomfort. In clinical trials, a significantly higher proportion of patients using the medication were reported to be pain-free as early as Day 1 following cataract surgery, compared to those using a placebo.

Q: Does Bromfenac help with redness in the eye, or just pain?

Bromfenac is officially indicated for the treatment of postoperative inflammation and the reduction of ocular pain. Inflammation often includes symptoms like redness and swelling. Clinical studies used the clearance of ocular inflammation as a key measure of the drug's effectiveness.

Q: Can Bromfenac eye drops cause blurred vision?

Yes, regulatory documents indicate that blurred vision is a common adverse reaction reported by patients using Bromfenac eye drops. Official labeling indicates that vision may become temporarily blurred immediately after application.

Q: Is it normal to feel a stinging sensation right after putting in Bromfenac drops?

According to the official product information, eye irritation is listed as a common adverse reaction reported in clinical trials. This general category of irritation can include sensations such as stinging or burning immediately after the drop is administered.

Q: What if I accidentally put more than one drop of Bromfenac in my eye?

The regulatory labeling does not provide specific instructions for an accidental single-application overdose. It emphasizes adhering strictly to the prescribed application of one drop and cautions against using the medication more often than directed.

Q: What should I look out for that would be a serious side effect of Bromfenac?

The official label advises that patients with signs of corneal epithelial breakdown (such as worsening pain, severe redness, or discharge) should immediately discontinue use and be monitored. Serious allergic reactions, such as breathing difficulties, are also a rare risk.

Q: Does Bromfenac have a strong odor or taste if it drains down the throat?

The Bromfenac eye drop formulation is intended for topical ocular use and is designed to minimize systemic exposure, meaning the amount of drug that enters the bloodstream is very low. Official regulatory documents do not list taste or odor as a reported adverse reaction.

Q: Do you need a prescription for Bromfenac eye drops?

Yes, Bromfenac ophthalmic solution is classified as a prescription-only medicine for topical ophthalmic use. It must be administered under the guidance of a healthcare professional.

Q: Are there any major diet restrictions while using Bromfenac?

The official regulatory labeling for Bromfenac ophthalmic solution does not list any specific food or major diet restrictions for its use.

Q: Will using Bromfenac make my eyes sensitive to light?

Yes, official regulatory documents indicate that photophobia (an increased sensitivity of the eyes to light) is listed as an adverse reaction reported in clinical trials.

Q: Is Bromfenac safe to use if I have high blood pressure?

The official regulatory labeling for the eye drop formulation does not list high blood pressure as a specific contraindication or special caution for use. The primary warnings focus on local effects like corneal health and bleeding risks.

Q: Is it okay to use my regular over-the-counter eye drops with Bromfenac?

Yes, Bromfenac may be administered with other topical ophthalmic medications. Official guidance requires that all other topical drops be administered at least 5 minutes apart from Bromfenac to prevent dilution.

Q: Does sun exposure make side effects from Bromfenac worse?

The official regulatory labeling does not contain a warning regarding sun exposure or photosensitivity in relation to the potential adverse effects from the eye drop formulation.

Q: Are there generic versions of Bromfenac eye drops available?

Yes, Bromfenac ophthalmic solution is available as a generic formulation, in addition to the original brand-name products. Both generic and brand-name versions contain the same active ingredient.

Q: What are the ingredients in Bromfenac besides the active drug?

Besides the active drug, the product contains inactive ingredients. These typically include a preservative, such as benzalkonium chloride, and may contain stabilizing components like boric acid, sodium sulfite, and other agents for pH adjustment.

Q: Can Bromfenac eye drops make my contacts feel uncomfortable?

The label advises removing contact lenses before using the drops because the preservative may be absorbed by soft lenses and could cause irritation. Official patient counseling states that lenses may typically be reinserted after 10 minutes following the dose.

Q: Can I drive after using Bromfenac eye drops?

Because the medication can cause temporary blurred vision right after use, official advice is to wait until vision clears before driving or operating machinery.

Q: Is Bromfenac safe for people with diabetes?

Patients with diabetes mellitus are advised to use the medication with caution and require close monitoring by a healthcare provider due to an elevated risk of corneal adverse events.

Q: What is the shelf life of Bromfenac eye drops once the bottle is opened?

Official guidance requires that patients discard any unused contents after a certain period following the first opening, such as 4 weeks for some product formulations. This is necessary to maintain sterility.

Q: Are there any studies comparing Bromfenac to a placebo?

Yes, the effectiveness of Bromfenac was established through placebo (vehicle)-controlled clinical trials. These studies compared the Bromfenac solution directly to a non-medicated eye drop vehicle to confirm the medication's benefit.

Q: Does the strength of Bromfenac (like 0.09% or 0.1%) make a big difference?

Different approved product strengths, such as 0.07%, 0.075%, and 0.09%, are associated with different dosing schedules (e.g., once daily versus twice daily) as determined necessary to achieve the desired therapeutic effect.

Q: How common is an allergic reaction to Bromfenac?

While severe allergic reactions (such as those related to sulfite sensitivity) are possible, the overall prevalence of these reactions in the general population is generally considered low. The official label reports allergic-type reactions as rare post-marketing events.

Q: Can Bromfenac be used for general eye irritation not related to surgery?

No, the official regulatory indication for this medication is specifically for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery.

Q: What are the long-term risks associated with Bromfenac use?

Bromfenac is prescribed for a short treatment course post-surgery. Regulatory warnings indicate that the risks of severe corneal events (such as thinning, erosion, and perforation) are elevated with prolonged use beyond the recommended duration.

How should Bromfenac be stored and disposed of?

How to Store and Dispose of Bromfenac Ophthalmic Solution

Bromfenac ophthalmic solution must be stored according to official regulatory labeling to ensure stability and prevent contamination.

Storage Requirements

Condition	Regulatory Rule
Temperature	Store at 15 C to 25 C (59 F to 77 F) (Controlled Room Temperature).
Protection	Keep the medicine away from heat, moisture, and direct light; keep from freezing.
Container	Keep the container tightly closed and in its original packaging. Do not touch the dropper tip to any surface.
Child Safety	Store the medication out of the reach and sight of children.

Disposal Instructions

Expiration and stability rules require discarding any unused contents according to the specific product label, such as 4 weeks after first opening for some regional formulations, or after the treatment is finished. Patients must dispose of all unused medicinal product or waste material in accordance with local requirements.

Bromfenac